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Abstract 
Recent protocols have been developed to differentiate human stem cells and 
fibroblasts into insulin-producing cells capable of releasing the hormone in a glucose-
stimulated manner. Limitations remain which prevent bringing these protocols to a 
clinical setting as these models must still undergo complete characterization. 
Advances in sequencing technologies have driven the identification of several non-
coding RNA species including microRNAs (miRNAs). While their diversity and 
unique expression patterns across different tissues have made deciphering their 
precise functional role a significant challenge, studies using both cell lines and 
transgenic mouse models have made substantial progress in understanding their 
regulatory role on exocytosis and proliferation of the β-cell. These results also 
indicate miRNAs play an integral role in the fundamental mechanics of how the cell 
manages the balance between these independent functions. Continued investigation 
into miRNA function may uncover mechanisms which can be exploited to improve 
differentiation protocols in producing fully mature β-cells. 
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Glucose homeostasis and the pancreatic β-cell 
The metabolism of glucose as a source of energy is a fundamental property virtually 
all cell types share from bacteria to humans [1]. As mammals have evolved and their 
cells increased their diversity over time, so has the expression pattern of genes which 
regulate the breakdown of glucose as a cellular fuel. Among the most studied 
mechanisms is the pancreatic β-cell which regulates its output of insulin as part of a 
complex endocrine network of signaling molecules designed to maintain stable 
glucose concentrations. In addition to adjusting its secreted load, the β-cell will also 
adapt its transcriptional programming to promote its proliferation in response to 
chronic hyperglycemia however it remains unclear how the cell simultaneously 
balances the energy requirements of both processes [2]. Recent technological 
breakthroughs have enabled the systematic discovery of several new regulatory 
molecules which have begun to shed new light on the intracellular mechanisms of 
the β-cell. The advancement of high-throughput sequencing facilitated the 
identification of several classes of non-coding RNA species including miRNAs 
(miRNAs) and a canonical pathway has been established describing the processing 
and incorporation of these small RNAs into Argonaute-containing complexes [3]. 
These discoveries  have led to a surge in research into exploration of the functional 
role of post-transcriptional gene regulation within the cell [4]. Here we explore the 
current state of the art of research into miRNAs and their role in the pancreatic β-cell 
and how these studies may offer insights into cell types central to the maintenance of 
energy and glucose homeostasis in the body. 
 
MicroRNA profiling in the pancreatic β-cell and islets 
The initial paper reporting the first cloning effort of miRNAs in the pancreatic β-cell 
identified 67 unique sequences including miR-375 [5]. As current sequencing 
technologies have long rendered this cloning method obsolete, they have also 
revealed the potential for hundreds of unique functional sequences to be present in 
most cell types including the β-cell. To date, 2588 mature human miRNAs have been 
annotated in the miRBase database V20 which now catalogs 206 different plant and 
animal species [6]. While several sequences including miR-375, miR-7, and miR-184 
appear to be enriched in the endocrine pancreas, profiling results from mouse and 
human tissues have shown that none of these miRNAs are entirely specific to the islet 
[7] [8]. In the case of miR-375, expression of this miRNA has been reported in 
numerous tissue types including the pituitary gland, adrenal gland, intestine, lung, and 
several types of cancer [9] [10]. Similarly, miR-7 and miR-184 have been shown to 
be highly enriched in the central nervous system and eye, respectively [11]. Recent 
studies using mouse knockouts have shown that loss of these three abundant miRNAs 
will increase β-cell exocytosis however it still remains unclear whether all miRNAs 
present in the β-cell are committed to an identical functional role and whether they 
perform the same function in all cell types where they are present [12] [9] [8]. For 
example, while miR-375 regulates exocytosis and compensatory proliferation of the 
β-cell, it has not been determined whether it functions in these capacities in the other 
neuroendocrine cell types where it is expressed [8] [13]. Meanwhile for miRNAs 
which are abundant in the β-cell however are ubiquitously expressed across many 
tissues such as the let-7 family, it is not clear whether there is functional overlap to 
sequences like miR-375. Transgenic over-expression of let-7 resulted in glucose 
intolerance in mice, however it is not clear if this microRNA regulates β-cell mass or 
function [14]. 
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In light of the diversity of the miRNA profile of the β-cell in terms of number of 
sequences and their expression levels, several important questions remain to be 
addressed for future studies. The issue of combinatorial targeting of genes by multiple 
miRNAs has not been well studied in vivo however the advent of new methodologies 
including CRISPR/Cas9 site-directed mutagenesis and crosslinking-
immunoprecipitation (CLIP) protocols can now expedite the identification of 
biologically relevant cis and trans sequences [15] [16]. In addition to improving our 
understanding miRNA target recognition, these protocols have the potential of 
establishing the functional importance of low expressed sequences either by loss of 
function studies or by identifying robust miRNA : target gene interactions. 
 
Elucidating the functional role of microRNAs in the β-cell 
Without any doubt, in recent years significant progress has been achieved in 
understanding miRNAs as regulators of gene expression throughout all areas of 
biology [3]. As mentioned previously, substantial investment in high throughput 
sequencing has all but ruled out the possibility of identifying novel abundant 
sequences and the majority of investigators have since directed their attention on 
addressing specific biological questions. The chronic hyperglycemia characteristic of 
diabetes has long been established the result of inadequate insulin action making one 
of the prime directives of the β-cell field to identify genes and mechanisms which 
contribute to reduced growth and function of this cell type. Since the first gain and 
loss of function studies on miR-375, several subsequent reports have identified a 
number of additional miRNAs as negative regulators of β-cell function including 
miR-7, miR-184, miR-21, miR-29a and miR-33a [5] [12] [8] [17] [18]. Importantly, 
the role of several miRNAs as negative regulators has been substantiated using 
specific genetic mouse knockouts [19]. Likewise, the siRNA-mediated knockdown 
of Argonaute2 (Ago2), a key mediator of miRNA function in all cell types, also 
resulted in increased secretory capacity further supporting the notion that several 
prominent if not the majority of miRNAs act as negative regulators of exocytosis 
[13]. While it still remains a possibility that some miRNAs target genes that result in 
an overall positive effect on insulin release, the published data to date points toward 
an overall inhibitory effect by the pathway on β-cell exocytosis.  
 
With respect to miRNAs and their role in growth and proliferation of the β-cell, a 
number of significant observations have been made that also affirm a significant 
functional role for small RNAs in this cell type. The mouse knockout of miR-375 
exhibited a decrease in β-cell mass at steady state that was further exacerbated once 
the model was crossed into the ob/ob background [9]. This result provided the first in 
vivo evidence that miRNAs could play a binary role in regulating both exocytosis and 
cellular proliferation. β-cell specific knockout mouse of Ago2, a key mediator of the 
miRNA pathway, exhibited a similar phenotype underlining an important role for 
small RNAs in the compensatory response of this cell type as the demand for insulin 
increases [8]. As potent regulators of both secretion and cell proliferation, together 
these results highlight the potential for studying how this pathway contributes to the 
most fundamental aspects of β-cell physiology. Future studies can now aim at 
exploring the precise mechanisms of their function including dissecting their distinct 
contribution to both exocytosis and proliferation, identifying interacting RNA binding 
proteins and specific RNA modifications which may impact miRNA function, 
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expression and localization, and the full extent to which the target genes in the β-cell. 
 
Identification of microRNA targets in the β-cell 
As the miRNA field began to gain momentum and the numbers of small RNAs 
rapidly increased across different species, it became readily apparent that the 
identification of direct targets required the specialized expertise of computational 
investigators to develop algorithms that could locate putative binding sites in the 
genome. Among the first successes in vivo was observed in Drosophila by Cohen and 
colleagues with the identification of the miRNA bantam targeting the pro-apoptotic 
gene hid [20]. The first mammalian target myotrophin (Mtpn) was shown to be 
regulated by miR-375 using a murine insulinoma cell line MIN6 [5]. Based on these 
first observations, both empirical and computational evidence influenced the 
development of the first miRNA target algorithms implementing cross-species 
conservation [3] [21]. Since these early model studies, the TargetScan algorithm has 
continued to refine its target predictions and remains among the most recognized in 
the field [22]. Recent reports have implemented biochemical approaches (crosslinking 
and immunoprecipitation, CLIP) to identify specific miRNA target sites by isolating 
and sequencing the 3’UTR region bound by Ago proteins [16]. While these protocols 
are currently dependent upon large quantities of source tissue material in cell culture, 
this limitation excludes the possibility of studying human islets however the 
development of the stem cell differentiation protocols may make the CLIP protocol 
viable for human β-cells in the near future. A recent study profiling miRNAs after the 
immunoprecipitation of Ago proteins revealed stark differences in the small RNA 
profile suggesting biochemical approaches to profile miRNAs in FACS-sorted human 
β-cells may provide insight into distinct populations of miRNAs which interact with 
specific RNA binding proteins [4] [23]. To date, numerous studies have established 
specific miRNA:target gene interactions implicating the entire range of β-cell 
physiology and it appears likely that eventually every functional category (i.e. 
receptors, signaling, kinases, channels, etc.) and pathway (p53, G-protein coupled 
receptor, PLC, etc.) will be recognized as being targeted by miRNA [24] [25] [26]. 
Therefore it is imperative for the field to now put these observations in perspective 
and understand the implications of miRNA function in the β-cell. What important 
questions should be addressed and can this mechanism be exploited for the 
development of future therapeutic strategies? 
 
One perspective on microRNAs in the β-cell 
A great deal remains to be described with respect to the collective function of all 
miRNAs expressed in the β-cell. As computational algorithms have identified 
putative miRNA-binding sites in the 3’UTRs of the majority of annotated genes, it is 
still not precisely known why this form of gene regulation exists [22]. Several 
hypotheses have been proposed on the role of miRNAs and one that is highly 
plausible suggests that miRNAs anneal to transcripts to inhibit translation as demand 
for the expression of the mRNA subsides [3] [19]. In the context of the pancreatic β-
cell, there are several reasons why this hypothesis is fitting. First, several mechanisms 
exist in the body beyond the cells of the endocrine pancreas to attenuate and counter 
insulin action as preventative measures against hypoglycemia [27]. Most notably is 
the release of glucagon by the α-cells of the pancreas to promote gluconeogenesis in 
the liver. However during and after food intake, in response to an increase in the 
concentration of extracellular glucose, hundreds of genes will contribute to the series 
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of mechanistic events starting with glycolysis, mitochondrial function, the formation 
and trafficking of insulin granules, and ultimately exocytosis [28]. Therefore, it is 
reasonable to speculate that the profile of miRNAs present in the β-cell may have 
diversified to specifically suppress these genes due to their unique functional 
mandate: to systematically regulate insulin release. It is widely reported that the β-cell 
releases only a small percentage of its stored granule pool in response to glucose 
further supporting the notion that exocytosis from the β-cell is a highly regulated 
process [29] [28]. Therefore the presence of miRNAs may simply serve to manage 
and synchronize the efficient output of insulin. As observed in the mouse knockouts 
of miR-375, miR-7, miR-184 and Ago2 in the β-cell, loss of expression of these 
molecules results in the hypersecretion of insulin and the enrichment of these 
sequences in the β-cell act to target its distinct profile of genes. Just as 
cardiocmyocytes, excitatory neurons, hepatocytes, and adipocytes maintain specific 
functional roles; their microRNA profiles are also distinct to their mRNA expression 
profiles.  
 
In light of the abundance of literature highlighting the diversity of non-coding RNAs 
in terms of sequence and function, labeling miRNAs in the β-cell as ‘inhibitors of 
insulin release’ is an over-simplification of the matter. To further address how 
miRNAs meet the role as regulators of gene expression according to metabolic 
demand, an additional layer to this hypothesis centers on the signals which instigate 
insulin release. The discussion here began with glucose metabolism and insulin is 
released by the β-cell primarily to direct glucose uptake in peripheral skeletal muscle 
and adipose tissue. Therefore, the question is now: how do miRNAs function 
according to the rise and fall of glucose levels? In the post-prandial state, as 
extracellular glucose concentrations subside within hours, it is not clear whether these 
transcripts encoding secretion-mediating genes are quickly degraded or rather 
stabilized in preparation for subsequent metabolic signals. Therefore, one possible 
function for miRNAs may be to bind these mRNAs in a sequence specific manner 
with the assistance of RNA-binding proteins (i.e Argonautes) in order to protect and 
delay degradation over the course of several hours [30] [31]. In the event that 
extracellular glucose levels again arise within an acute time frame, the miRNAs can 
then be ‘de-recruited’ from these transcripts to facilitate expression of the proteins 
regulating the breakdown of glucose and insulin release. The annealing of miRNAs to 
target transcripts may act to preserve these mRNAs which are in continual demand 
(i.e. when meals are minutes and hours apart).  Additional signals may ultimately 
promote the degradation of these mRNAs once the demand has ceased (i.e. during 
prolonged fasting or sleep). This idea also coincides with the majority of studies 
showing the regulation of putative target genes after increasing or decreasing miRNA 
function in excess of 24 hours or the time to transfect cells in culture [3]. This 
hypothesis on miRNA function suggests these non-coding RNAs could serve as an 
energy-efficient means of regulating transcription and gene expression in contrast to 
continuous de novo synthesis and degradation of mRNAs as the demand for insulin 
rises and falls. As mentioned previously, several tissues coordinately maintain 
systemic glucose levels near 5mM and the hypothesis here proposes that miRNAs in 
the β-cell act at least in part as a safeguard to strictly regulate exocytosis. 
 
The next question with respect to miRNA function extends to chronic increases in 
glycemia as characterized by individuals with diabetes. How do miRNAs contribute 
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to β-cell function in the context of metabolic disease? If miRNAs are hypothesized 
here to strictly regulate secretion, in the presence of hyperglycemia, are these non-
coding RNAs then in a state of ‘de-recruitment’ of their target mRNAs to facilitate 
increased exocytosis? In short, there are reasons to believe the answer is no, miRNAs 
still act to strictly regulate secretion even during chronic hyperglycemia. Another 
important aspect of β-cell function is its concomitant ability to proliferate to increase 
cellular number and mass in response to increased demand for insulin and glucose has 
long been known as a potent regulator of β-cell proliferation [32] [33] [34]. The 
mouse knockouts for miR-375 and Ago2 in the β-cell both showed loss of 
compensatory proliferation after crossing these models onto the ob/ob background 
indicating miRNA function is essential for this adaptive response. Therefore if 
miRNA function is necessary to maintain the proliferative capacity of these cells 
when confronted by hyperglycemia and insulin resistance, is this function exclusive 
of its role in regulating secretion? Perhaps not. With respect to the ob/ob model, 
pancreatic β-cell mass has been shown to be increased ~8-fold and circulating insulin 
levels were measured increased over ~30-fold compared to wild-type littermate 
controls making it clear that proliferation has been increased to accommodate the 
increased insulin demand [8]. If miRNA function is essential for compensatory 
proliferation, it is reasonable to speculate that secretion may be compromised in order 
for the β-cell to devote its energy resources into cellular replication. Can the 
population of β-cells afford to limit secretion under these circumstances when 
demand is elevated? In the case of the ob/ob model, clearly it can as evidenced by 
plasma insulin levels of ~30-50 ng/mL [35]. In the presence of hyperglycemia and 
insulin resistance (at least in the case of ob/ob mice), the β-cell appears to deem 
proliferation and increasing mass to be preferential over increasing exocytosis to 
achieve demand. It is important to note that the role of miRNAs in inhibiting insulin 
release has never been shown to equate with complete suppression of the pathway and 
this is also fitting with its role as a ‘modulator’ of exocytosis. Therefore to attenuate 
secretion by 25 or even 50% its normal rate, may be necessary for conserving the 
resources of the cell after increasing β-cell mass by ~8-fold. Especially under chronic 
conditions of hyperglycemia and insulin resistance, the reduced secretory output may 
not only be necessary to maintain proper internal dynamics of the cell but it may also 
be inconsequential over the course of a 24-hour period. Under chronic conditions, the 
β-cell may simply operate with reduce output for extended durations of time 
compared to when the cell is challenged under more acute conditions.  
 
In summary, the hypothesis outlined here proposes a role for miRNAs in the β-cell 
whereby their function is tightly linked to the energetics of the cell. As stipulated by 
the first law of thermodynamics, energy in a closed system will always remain 
conserved [36]. To extrapolate this principle to the β-cell, it is reasonable to presume 
that in the presence of increased glucose concentrations, the cell does not have the 
capacity to simultaneously increase secretion and promote proliferation and recent 
evidence from genetic knockout models support this hypothesis. To substantiate this 
view, additional studies need to address how precisely miRNAs manage this balance. 
Do all of the genes targeted by the miRNAs contribute to both cell proliferation and 
exocytosis? Might RNA-binding proteins respond to metabolic signals and dictate the 
targeting of genes which drive the cell toward exocytosis and away from proliferation 
and vice versa [31]? Are miRNAs modified to alter their function [37]? Future studies 
may also determine that the inability of miRNAs to manage both adaptive 
 8 
proliferation and the modulation of insulin release are hallmarks of β-cell failure and 
ultimately lead the cell on a path to either apoptosis or de-differentiation [38]. 
 
Perspectives Beyond the β-cell 
The views offered here draw from more than a decade of research in the field of 
miRNAs and the β-cell and at this stage it is prudent to also examine how these 
hypotheses may extend beyond this one specific cell type. As mentioned in the 
introduction of this review, the metabolism of glucose extends to virtually all living 
organisms and as cells in mammalian systems began to diversify, so did the genes 
which manage the energy resources of the cell. In comparing humans to less complex 
organisms such as the worm and fly, while insulin-related peptides and their signaling 
cascades are conserved great distances, the majority of miRNAs are not perhaps 
owing to several reasons: a decrease in tissue complexity, differences in energy 
requirements, and lifespan [39] [40] [41]. MiRNAs may have simply evolved as 
organisms and their cellular make-up transformed with respect to size, complexity, 
and demand for energy. 
 
Glucokinase in mammals is abundant in the liver hepatocyte, endocrine pancreas, 
neurons of the brain, and the gut; however its expression becomes more limited in 
organisms that are more distantly related to humans [42]. Can observations in the b-
cell be extended to other key tissues involved in glucose and energy homeostasis? The 
liver maintains a high regenerative capacity and maintains a central role in both 
glucose and lipid metabolism and it would be of great interest to determine whether 
the miRNA pathway is integral to balancing these processes in the hepatocyte [43]. In 
the steady state, proliferation rates are low, however it is unclear whether its function 
in gluconeogenesis, glycogen storage, and lipid oxidation are compromised as soon as 
the cell’s demand for growth are increased [44]. The intestine is also known for its 
high capacity for glucose utilization and proliferation, however it is also unclear 
whether miRNAs play a role in this tissue to maintain the balance of these functions 
[45]. Lastly, in humans, the central nervous system maintains the highest demand for 
energy requiring a continuous supply of glucose from the blood [46]. While 
proliferation rates throughout the central nervous system are difficult to detect, 
glucose metabolism is linked with several aspects of cellular physiology of the brain 
including signaling, plasticity and synapse formation. In light of the high degree of 
overlap between the β-cell and neurons of the brain in terms of gene expression, it 
also worthy to address whether miRNAs contribute to the adaptive processes of the 
nervous system as they relate to glucose metabolism, synaptic transmission and 
axonal assembly. 
 
Summary 
As miRNAs continue to be linked to each aspect of β-cell physiology including 
insulin expression, vesicle trafficking and exocytosis, mitochondrial function, and 
proliferation, these observations indicate miRNAs contribute to every fundamental 
property of this cell type. While many key questions regarding their cellular role 
remain to be answered, it is clear going forward that miRNAs as well as other non-
coding RNAs will ultimately be viewed as important regulators of gene expression. In 
the entire context of the cellular machinery, miRNAs will presumably soon be viewed 
as one of the many factors which bind mRNAs to either inhibit their translation or 
facilitate degradation according to the metabolic context of the cell (i.e. extracellular 
glucose levels). To bring additional clarity to this picture, future studies should 
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address the global temporal regulation and stability of β-cell transcripts in response to 
changes in extracellular glucose concentrations. The crosslinking protocols that have 
been developed to identify target sites of miRNAs and RNA-binding proteins can be 
implemented on the stem cell and fibroblast models now available to understand how 
non-coding RNAs function in as cells differentiate into insulin-producing β-cells [47] 
[48] [49] [50]. Improving these protocols to optimize the functional properties and 
viability of these β-cell models remain a top priority for the development of future 
therapeutic strategies for combating diabetes.  
 
Practice Points 
• A greater understanding of the functional role of miRNAs in the β-cell could 
improve stem cell differentiation protocols to enhance secretory function, 
insulin production, and viability 
 
Research Agenda 
• How do miRNAs precisely contribute to the management of the balance 
between growth and secretion?  
• To what extent and which RNA binding proteins mediate miRNA function?  
• In which cellular compartments to miRNAs function and reside?  
• To what extent are miRNAs modified and how might this impact their 
function?  
• How does the half-life of a miRNA impact its function? 
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